More articles from Neurosciences/Neurology. Neurocognitive disorders

You have access
Metabolic Phenotype on F-18 FDG PET/CT and sleep architecture in Mild cognitive Impairment.
Madhavi Tripathi, Manjari Tripathi, Parul Thakral, Sadanand Dwivedi, Nishikant Damle, Ashima Nehra and Chandrasekhar Bal

Journal of Nuclear Medicine May 1, 2016, 57 (supplement 2) 234;
You have access
ASL as a substitute for [18F]FDG? - A simultaneous brain PET/MRI study
Henryk Barthel, Peter Werner, Michael Rullmann, Toralf Mildner, Solveig Tiepolt, Hermann-Josef Gertz, Matthias Schroeter, Dorothee Saur, Harald MÃ¶ller and Osama Sabri

Journal of Nuclear Medicine May 1, 2016, 57 (supplement 2) 235;
You have access
Automated PET-only quantification of amyloid deposition with adaptive atlas and empirically pre-defined ROI template
Go Akamatsu, Yasuhiko Ikari, Akihito Ohnishi, Tomoyuki Nishio, Hiroyuki Nishida, Yasuji Yamamoto, Masayuki Sasaki and Michio Senda

Journal of Nuclear Medicine May 1, 2016, 57 (supplement 2) 239;
You have access
Correlation of metabolic and volumetric metrics of the structures of the temporal lobe on MRI and FDG-PET in patients with mesial temporal sclerosis
Carlos Leiva Salinas, Nathan Fountain, Mark Quigg, W Jeffrey Elias, James Patrie and Patrice Rehm

Journal of Nuclear Medicine May 1, 2016, 57 (supplement 2) 236;
You have access
Alterations in neurocognitive networks in dementing disorders as assessed with simultaneous PET/fMRI
Thomas Stadhouders, Alexandre Savio, Janine Diehl-Schmid, Christian Sorg, Timo Grimmer and Igor Yakushev

Journal of Nuclear Medicine May 1, 2016, 57 (supplement 2) 237;
You have access
Cerebral glucose metabolic reduction patterns of PiB accumulation positive and negative cognitive disordered subjects
Chisa Hosokawa, Kazunari Ishii, Yuichi Kimura, Hayato Kaida, Yuichi Wakabayashi, Tomoko Hyodo, Makoto Hosono and Takamichi Murakami

Journal of Nuclear Medicine May 1, 2016, 57 (supplement 2) 238;
You have access
Changes in regional cerebral blood flow associated with a 45 day course of the ketogenic agent, caprylidene, in patients with mild to moderate Alzheimer’s disease: results of a randomized, double-blinded, pilot study
Chakmeedaj Sethanandha, Michelle Dilley, Joshua Grill, Jooyeon Lee, Jeffrey Cummings, Celine Ossinalde, Erica Parker and Daniel Silverman

Journal of Nuclear Medicine May 1, 2016, 57 (supplement 2) 233;

Main menu

User menu

Search

More articles from Neurosciences/Neurology. Neurocognitive disorders